A yeast-based in vivo bioassay to screen for class i phosphatidylinositol 3-kinase specific inhibitors

Journal of Biomolecular Screening

Volumn 17, Issue 8, 2012, Pages 1018-1029

  Fernández Acero, Teresa ^a   Rodríguez Escudero, Isabel ^a   Vicente, Francisca ^b   Monteiro, Maria Cândida ^b   Tormo, José R ^b   Cantizani, Juan ^b   Molina, María ^a   Cid, Víctor J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b Fundacion MEDINA   (Spain)

Author keywords

cell based assays; high throughput screening (HTS); in vivo screening; phosphatidylinositol 3 kinase (PI3K); yeast screening technology

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 MORPHOLINO 2 PHENYLQUINAZOLINE; DODECYL SULFATE SODIUM; NATURAL PRODUCT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTRELISIB; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DETOXIFICATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HETEROLOGOUS EXPRESSION; HIGH THROUGHPUT SCREENING; IN VIVO STUDY; LARGE SCALE PRODUCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPRODUCIBILITY; SACCHAROMYCES CEREVISIAE; SECOND MESSENGER; SENSITIVITY ANALYSIS;

ATP-BINDING CASSETTE TRANSPORTERS; FURANS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; PYRIMIDINES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SODIUM DODECYL SULFATE;

EID: 84864967756     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112450051     Document Type: Article

References (35)

1. Vogt P. K., Hart J. R., Gymnopoulos M., Jiang H., Kang S., Bader A. G., Zhao L., Denley A.. Phosphatidylinositol 3-kinase: the oncoprotein. Curr. Top. Microbiol. Immunol. 2010 ; 347: 79-104
2. Fayard E., Xue G., Parcellier A., Bozulic L., Hemmings B. A.. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr. Top. Microbiol. Immunol. 2010 ; 346: 31-56
3. Courtney K. D., Corcoran R. B., Engelman J. A.. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 2010 ; 28: 1075-1083
4. Rodriguez-Escudero I., Oliver M. D., Andres-Pons A., Molina M., Cid V. J., Pulido R.. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes. Hum. Mol. Genet. 2011 ; 20: 4132-4142
5. Khwaja A.. PI3K as a target for therapy in haematological malignancies. Curr. Top. Microbiol. Immunol. 2010 ; 347: 169-188
6. Ghigo A., Damilano F., Braccini L., Hirsch E.. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays. 2010 ; 32: 185-196
7. Marone R., Cmiljanovic V., Giese B., Wymann M. P.. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta. 2008 ; 1784: 159-185
8. Shuttleworth S. J., Silva F. A., Cecil A. R., Tomassi C. D., Hill T. J., Raynaud F. I., Clarke P. A., Workman P.. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr. Med. Chem. 2011 ; 18: 2686-2714
9. Brachmann S., Fritsch C., Maira S. M., Garcia-Echeverria C.. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr. Opin. Cell. Biol. 2009 ; 21: 194-198
10. Maira S. M., Finan P., Garcia-Echeverria C.. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr. Top. Microbiol. Immunol. 2010 ; 347: 209-239
11. Dobson C. M.. Chemical space and biology. Nature. 2004 ; 432: 824-828
12. Mager W. H., Winderickx J.. Yeast as a model for medical and medicinal research. Trends Pharmacol. Sci. 2005 ; 26: 265-273
13. Bjornsti M. A.. Cancer therapeutics in yeast. Cancer Cell. 2002 ; 2: 267-273
14. Cid V. J., Rodriguez-Escudero I., Andres-Pons A., Roma-Mateo C., Gil A., den Hertog J., Molina M., Pulido R.. Assessment of PTEN tumor suppressor activity in nonmammalian models: the year of the yeast. Oncogene. 2008 ; 27: 5431-5442
15. Rodriguez-Escudero I., Roelants F. M., Thorner J., Nombela C., Molina M., Cid V. J.. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem. J. 2005 ; 390: 613-623
16. Andres-Pons A., Rodriguez-Escudero I., Gil A., Blanco A., Vega A., Molina M., Pulido R., Cid V. J.. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer Res. 2007 ; 67: 9731-9739
17. Rodriguez-Escudero I., Andres-Pons A., Pulido R., Molina M., Cid V. J.. Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations. J. Biol. Chem. 2009 ; 284: 13373-13383
18. Rodriguez-Escudero I., Rotger R., Cid V. J., Molina M.. Inhibition of Cdc42-dependent signalling in Saccharomyces cerevisiae by phosphatase-dead SigD/SopB from Salmonella Typhimurium. Microbiology. 2006 ; 152: 3437-3452
19. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
20. Kümmel A., Gubler H., Gehin P., Beibel M., Gabriel D., Parker C. N.. Integration of multiple readouts into the z' factor for assay quality assessment. J. Biomol. Screen. 2010 ; 15: 95-101
21. Vlahos C. J., Matter W. F., Hui K. Y., Brown R. F.. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4- one (LY294002). J. Biol. Chem. 1994 ; 269: 5241-5248
22. Hayakawa M., Kaizawa H., Moritomo H., Koizumi T., Ohishi T., Okada M., Ohta M., Tsukamoto S., Parker S., Workman P., et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors. Bioorg. Med. Chem. 2006 ; 14: 6847-6858
23. Zunder E. R., Knight Z. A., Houseman B. T., Apsel B., Shokat K. M.. Discovery of drug-resistant and drug- sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008 ; 14: 180-192
24. Melese T., Hieter P.. From genetics and genomics to drug discovery: yeast rises to the challenge. Trends Pharmacol. Sci. 2002 ; 23: 544-547
25. Fan Q. W., Knight Z. A., Goldenberg D. D., Yu W., Mostov K. E., Stokoe D., Shokat K. M., Weiss W. A.. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006 ; 9: 341-349
26. Yaguchi S., Fukui Y., Koshimizu I., Yoshimi H., Matsuno T., Gouda H., Hirono S., Yamazaki K., Yamori T.. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl. Cancer Inst. 2006 ; 98: 545-556
27. Folkes A. J., Ahmadi K., Alderton W. K., Alix S., Baker S. J., Box G., Chuckowree I. S., Clarke P. A., Depledge P., Eccles S. A., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008 ; 51: 5522-5532
28. Genilloud O., Gonzalez I., Salazar O., Martin J., Tormo J. R., Vicente F.. Current approaches to exploit actinomycetes as a source of novel natural products. J. Ind. Microbiol. Biotechnol. 2011 ; 38: 375-389
29. Gray A., Olsson H., Batty I. H., Priganica L., Downes P. C.. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal. Biochem. 2003 ; 313: 234-245
30. Stankewicz C., Rininsland F. H.. A robust screen for inhibitors and enhancers of phosphoinositide-3 kinase (PI3K) activities by ratiometric fluorescence superquenching. J. Biomol. Screen. 2006 ; 11: 413-422
31. Wolff M., Haasen D., Merk S., Kroner M., Maier U., Bordel S., Wiedenmann J., Nienhaus G. U., Valler M., Heilker R.. Automated high content screening for phosphoinositide 3 kinase inhibition using an AKT 1 redistribution assay. Comb. Chem. High Throughput Screen. 2006 ; 9: 339-350
32. Zhang X., Smith D. L., Meriin A. B., Engemann S., Russel D. E., Roark M., Washington S. L., Maxwell M. M., Marsh J. L., Thompson L. M., et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 892-897
33. Tribouillard D., Bach S., Gug F., Desban N., Beringue V., Andrieu T., Dormont D., Galons H., Laude H., Vilette D., et al. Using budding yeast to screen for anti-prion drugs. Biotechnol. J. 2006 ; 1: 58-67
34. Jiang H., Shang X., Wu H., Gautam S. C., Al-Holou S., Li C., Kuo J., Zhang L., Chopp M.. Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J. Exp. Ther. Oncol. 2009 ; 8: 25-33
35. Parish C. A., de la Cruz M., Smith S. K., Zink D., Baxter J., Tucker-Samaras S., Collado J., Platas G., Bills G., Díez M. T., et al. Antisense-guided isolation and structure elucidation of pannomycin, a substituted cis-decalin from Geomyces pannorum. J. Nat. Prod. 2009 ; 72: 59-62